Invivyd announces proposed public offering of common stock

* Invivyd (NASDAQ:IVVD [https://seekingalpha.com/symbol/IVVD]) has commenced an underwritten public offering of shares of its common stock.
* In addition, Invivyd intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the shares of Invivyd common stock sold in the public offering at the public offering price, less underwriting discounts and commissions.
* Invivyd intends to use the net proceeds that it will receive from the offering, together with its existing cash and cash equivalents, for trial protocol development, planning and advancement of the VYD2311 clinical program, research and development related to its pipeline programs such as respiratory syncytial virus (RSV) and measles, advancement of the Spike Protein Elimination and Recovery (SPEAR) Study Group efforts related to assessing the effects of monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, and for working capital and other general corporate purposes.
* Source: Press Release [https://seekingalpha.com/pr/20207171-invivyd-announces-proposed-public-offering-of-common-stock]

MORE ON INVIVYD

* Invivyd aligns with FDA on fast-track approval path for COVID-19 antibody VYD2311 [https://seekingalpha.com/news/4485867-invivyd-aligns-with-fda-on-fast-track-approval-path-for-covid-19-antibody-vyd2311]
* Seeking Alpha’s Quant Rating on Invivyd [https://seekingalpha.com/symbol/IVVD/ratings/quant-ratings]
* Financial information for Invivyd [https://seekingalpha.com/symbol/IVVD/income-statement]